Shades of chemical beauty: An overview of synthetic routes to some anticancer drugs

References

• (a) Potti, A.; Schilsky, R. L.; Nevins, J. R. Refocusing the war on cancer: The critical rope of personalized treatment. Cancer 2010, 2, 1–3; (b) Colditz, G. R.; Wolin, K. Y.; Gehlert, S. Applying what we know to accelerate cancer prevention. Sci. Transl. Med. 2012, 4, 127rv4; (c) Alison, M. R. Cancer. ELs, 2001, 1–8; (d) Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2013, 63, 11–30; (e) Bhattacharyya, S. Combitorial approached in anticancer drug discovery: Recent advances in design and synthesis. Curr. Med. Chem. 2001, 8, 1383–1404; (f) Borman, S. Agent boosts cancer cells, vulnerability, Chem. Eng. News 2012, 90, 20–27; (g) Neophytou, C. M., Constantinou, A. I. Drug delivery innovations for enhancing the anticancer potential of vitamin E isoforms and their derivatives. BioMed Research International, 2015, 2015, 584862–584877; (h) Jaouen, G., Vessières, A., Top, S. Ferrocifen type anti cancer drugs. Chem. Soc. Rev., 2015, 44, 8802–8817; (i) Paek, S.-M. Development of advanced Macrosphelides: Potent anticancer agents. Molecules 2015, 20, 4430–4449; (j) Russo, P.; Bufalo, A. D.; Fini, M. Deep sea as a source of novel-anticancer drugs: Update on discovery and preclinical/clinical evaluation in a systems medicine perspective. EXCLI J. 2015, 14, 228–236; (k) Gheybi, H.; Adeli, M. Supramolecular anticancer drug delivery systems based on linear–dendritic copolymers. Polym. Chem. 2015, 6, 2580–2615.
   Google Scholar
• Woo, L. W. L.; Fischer, D. S.; Sharland, C. M.; Trusselle, M.; Foster, P. A.; Chander, S. K.; Fiore, A. D.; Supuran, C. T.; De Simone, G.; Purohit, A.; Reed, M. J.; Poter, B. V. L. Anticancer steroid sulfatase inhibitors: Synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modelling, and protein crystallography. Mol. Cancer Ther. 2008, 7, 2435–2444.
   PubMed Web of Science ®Google Scholar
• Mozek, E.; Layman, R.; Ramaswamy, B.; Schaaf, L.; Li, X.; Ottman, S.; Shapiro, C. L. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clin. Breast Cancer 2012, 12, 151–156.
   PubMed Web of Science ®Google Scholar
• (a) Ghos, D.; Lo, J.; Morton, D.; Valette, D.; Xi, J.; Griswold, J.; Hubbell, S.; Egbuta, C.; Jiang, W.; An, J.; Davies, H. M. L. Novel aromatase inhibitors by structure-guided design. J. Med. Chem. 2011, 55, 8464–8476; (b) Suvannang, N.; Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachasittikul, V. Molecular docking of aromatase inhibitors. Molecules 2011, 16, 3597–3617.
   Web of Science ®Google Scholar
• Aggarwal, A. K.; Jain, A. K.; Chidambaram, V. S.; Wadhwa, L. Process for the preparation of Exemestane, PCT. International Publication Number WO 2010/076811 A2, 2010.
   Google Scholar
• (a) Mukherjee, A.; Narayan, K. P.; Pal, K.; Kumar, J. M.; Rangaraj, N.; Kalivendi, S. V.; Banerjee, R. Selective cancer targeting via aberrant behavior of cancer cells-associated glucocorticoid receptor. Mol. Ther. 2009, 4, 623–627; (b) Lewis, K. M.; Harford-Wright, E.; Vink, R.; Ghabriel, M. N. NK1 receptor antagonists and dexamethasone agents in vitro and a model of brain tumours secondary to breast cancer. Anticancer Drugs, 2013, 24, 344–354; (c) Wang, H.; Li, M.; Rinehart, J. J.; Zhang, R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemecitabine in mice bearing human cancer xenografts: In vivo activity. Clin. Cancer Res. 2004, 10, 1633–1644.
   Web of Science ®Google Scholar
• Ohta, T.; Zhang, H.; Torihara, Y.; Furukawa, I. Improved synthetic route to dexamethasone acetate from tigogenin. Org. Proc. Res. Dev. 1997, 1, 420–424.
   Web of Science ®Google Scholar
• (a) Herzog, H. L.; Nobile, A.; Tolksdorf, S.; Charney, W.; Hershberg, E. B.; Perlman, P. L.; Pechet, M. M. A new antiarthritic steroids. Science 1955, 121, 176; (b) Meystre, Ch.; Frey, H.; Voser, W.; Wettstein, A. Gewinnung von 1,4-bisdehydro-3-oxo-steroiden. Helv. Chim. Acta 1956, 39, 734–742; (c) Barton, D. H. R.; Morzycki, J. W.; Motherwell, W. B. Oxygen atom transfer from iodylbenzene to diphenyl diselenide-a convenient method for dehydrogenation of steroidal-ketones. J. Chem. Soc. Chem. Commun. 1981, 1044–1045; (d) Cairns, J.; Logan, R. T.; McGarry, G.; Roy, R. G.; Stevenson, D. F. M.; Woods, G. F. J. Chem. Soc. Perkin Trans. 1981, 1, 2306–2316; (e) Oliveto, E. P.; Rausser, R.; Weber, L.; Nussbaum, A. L.; Gebert, W.; Coniglio, C. T.; Hershberg, E. B.; Tolksdorf, S.; Eisler, M.; Perlman, P. L.; Pechet, M. M. 16-Alkylated corticoids. II.9α-fluoro-16α-methylprednisolone 21-acetate. J. Am. Chem. Soc. 1958, 80(16), 4431–4431.
   PubMed Web of Science ®Google Scholar
• Thundimadathil, J. Cancer treatment using peptides: Current therapies and future prospects. J. Amino Acids, 2012, 2012, 967347–967359.
   PubMedGoogle Scholar
• Jemal, A.; Bray, E.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90.
   PubMed Web of Science ®Google Scholar
• Kakde, D.; Jain, D.; Shrivastva, V.; Kakde, R.; Patil, A. T. Cancer therapeutics-opportunities, challenges and advance in drug delivery. J. Appl. Pharm. Sci. 2011, 1, 1–10.
   Google Scholar
• Enback, J.; Laakkonen, P. Tumour homing peptides: Tools for targeting, imaging and destruction. Biochem. Soc. Trans. 2007, 35, 780–783.
   PubMed Web of Science ®Google Scholar
• (a) Thayer, A. M. Improving peptides. Chem. Eng. News 2011, 89, 13–20; (b) Borghouts, C.; Kunz, C.; Groner, B. Current strategies for the development of peptide based anticancer therapeutics. J. Pep. Sci. 2005, 11, 713–726; (c) Sun, L. Peptide-based drug development. Mod. Chem. Appl. 2013, 1, 1–2.
   Web of Science ®Google Scholar
• Admas, I.; Kauffman, M. Development of the proteasome inhibitor velcade (Bortezomib). Can. Invest. 2004, 22, 304–311.
   PubMed Web of Science ®Google Scholar
• Meyers, P. A.; Schwartz, C. L.; Krailo, M.; Kleinerman, E. S.; Betcher, D.; Bernstein, M. L.; Conrad, E.; Ferguson, W.; Gebhard, M.; Goorin, A. M.; Harris, M. B.; Healey, J.; Huvos, A.; Link, M.; Montebello, J.; Nadel, H.; Nieder, M.; Sato, J.; Sieqal, G.; Weiner, M.; Wells, R.; Wold, L.; Womer, R.; Grier, H. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high dose methotrexate. J. Clin. Oncol. 2005, 23, 2004–2011.
   PubMed Web of Science ®Google Scholar
• Gelman, J. S.; Sironi, J.; Berezniuk, I.; Dasgupta, S.; Castro, L. M.; Gozzo, F. C.; Ferro, E. S.; Fricker, L. D. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One 2013, 8, e53263.
   PubMed Web of Science ®Google Scholar
• (a) Matteson, D. S., Boronic acids; D. G. Hall (Ed.); Wiley-VCH, 2005, 305–342; (b) Matteson, D. S. α-Halo boronic esters: Intermediates for stereodirected synthesis. Chem. Rev. 1989, 89, 1535–1551; (c) Matteson, D. S. Asymmetric synthesis with boronic acids. Acc. Chem. Res. 1988, 21, 294–300.
   Web of Science ®Google Scholar
• Ivanov, A. S.; Zhalnina, A. A.; Shishkov, S. V. A convergent approach to the synthesis of bortezomib: The use of TBTU suppresses racemization in the fragment condensation. Tetrahedron 2009, 65, 7105–7108.
   Web of Science ®Google Scholar
• Jackson, T.; Woo, L. W. L.; Trusselle, M. N.; Chander, S. K.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Dual aromatase-sulfate inhibitors based on the anasrozole template: Synthesis, in vitro SAR, molecular modelling and in vivo activity. Org. Biomol. Chem. 2007, 5, 2940–2952.
   Web of Science ®Google Scholar
• (a) Bajetta, E.; Martinetti, A.; Zilembo, N.; Pozzi, P.; Torre, I. L.; Ferrrari, L.; Seregni, E.; Longarini, R.; Salvucci, G.; Bombardieri, E. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: Effects on estrogens and bone metabolosim. Ann. Oncol. 2002, 13, 1059–1066; (b) Woo, L. W. L. Enzymes and their Inhibition; H. J. Smith, C. Simons (Eds.); CRC Press LLC: Boca Raton, 2005; pp. 221–241.
   PubMed Web of Science ®Google Scholar
• Brueggemier, R. W.; Hackett, J. C.; Diaz-Cruz, E. S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005, 26, 331–345.
   PubMed Web of Science ®Google Scholar
• (a) Miller, D. S.; Tai, D. F.; Obasaju, C.; Vergote, I. Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. Mod. Chemother. 2013, 2, 19–32; (b) Argiris, A.; Pennella, E.; Koustenis, A.; Hossian, A. M.; Obassaju, C. K. Pemetrexed in head and neck cancer: A systematic review. Oral Oncol. 2013, 49, 492–501.
   Google Scholar
• Vandana, M.; Sahoo, S. K. Reduced folate carrier independent internalization of PEGylated pemetrexed: A potential nanomedical approach for breast cancer therapy. Mol. Pharm. 2012, 9, 2828–2843.
   PubMed Web of Science ®Google Scholar
• Ciambecchini, U.; De Ferra, L.; Turchetta, S.; Zenoni, M.; Brandi, P. A novel process for the synthesis of pemetrexed disodium salt. European Patent Application, Application Number 11174646.7, 2012.
   Google Scholar
• Matthew, D. A.; Alden, R. A.; Bolin, J. T.; Freer, S. T.; Hamlin, R.; Xuong, N.; Kraut, J.; Poe, M.; Williams, M.; Hoogsteen, K. Dihydrofolate reductase: X-ray structure of the binary complex with methotrexare. Science 1977, 197, 452–455.
   PubMed Web of Science ®Google Scholar
• Rahman, K. A. L.; Chhabra, S. R. The chemistry of methotrexate and its analogues. Med. Res. Rev. 1988, 8, 95–155.
   PubMed Web of Science ®Google Scholar
• Norris, R. E.; Adamson, P. C. Clinical potency of methotrexate, aminopterin, talotrexin and pametrexed in childhood leukemias. Cancer Chemother. Pharmacol. 2010, 65, 1125–1130.
   PubMed Web of Science ®Google Scholar
• Rajagoplan, P. T. R.; Zhang, Z.; McCourt, L.; Dwyer, M.; Benkovic, S. J.; Hammes, G. G. Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics. Proc. Natl. Acad. Sci. 2002, 99, 13481–13486.
   PubMed Web of Science ®Google Scholar
• Goodsell, D. S. The molecular perspective: Methotrexate. Oncologist 1999, 4, 340–341.
   PubMedGoogle Scholar
• (a) Kar, A. Medicinal Chemistry. ISBN: 978-81-224-2305-7, 2013; (b) Cronstein, B. N.; Bertino, J. R.; Cronstein, B. N. Product Code: 25818000. ISBN: 3764359595, 2000.
   Google Scholar
• Ness, K. K.; Hudson, M. M.; Pui, C.-H.; Green, D. M.; Krull, K. R.; Huang, T. T.; Robinson, L. L.; Morris, E. B. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia. Cancer 2012, 118, 828–838.
   PubMed Web of Science ®Google Scholar
• Stover, E. In vitro cytotoxicity of the epothilone analog, BMS 247550, in pediatric malignancies. Centaurus 2002, 10, 31.
   Google Scholar
• Hussain, M.; Tangen, C. M.; Lara Jr, P. N.; Vaishampayan, U. N.; Petrylak, D. P.; Colevas, A. D.; Sakr, W. A.; Crawford, E. D. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-native patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111. J. Clin. Oncol. 2005, 23, 8724–8729.
   PubMed Web of Science ®Google Scholar
• Hunt, J. T. Discovery of ixabepilone. Mol. Cancer Ther. 2009, 8, 275–281.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Sun, B.-F.; Cui, K.; Lin, G.-Q. An efficient total synthesis of (–)–epothiolone B. Org. Lett. 2012, 14, 6354–6357.
   PubMed Web of Science ®Google Scholar
• Dickinson, M.; Prince, H. M. Romidepsin for relapsed and refractory cutaneous T-cell lymphoma. Clin. Med. Insights Dermatol. 2012, 5, 21–28.
   Google Scholar
• Samimi, S.; Morrissey, K.; Anshelevich, S.; Evans, K.; Gardner, J.; Musiek, A.; Vittoria, C.; Rook, A.; Kim, E. Romidepsin and interferon gamma: A novel combination for refractory cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2013, 68, e5–e6.
   PubMed Web of Science ®Google Scholar
• (a) Greshock, T. J.; Johns, D. M.; Noguci, Y.; Williams, R. M. Improved total synthesis of the potent HDAC Inhibitor FK228 (FE-901228). Org. Lett. 2008, 21, 613–616; (b) Narita, K.; Kikuchi, T.; Watanabe, K.; Takizawa, T.; Oguchi, T.; Kudo, K.; Matsuhara, K.; Abe, H.; Yamori, T.; Yoshida, M.; Katoh, T. Total synthesis of bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5″-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chem. Eur. J. 2009, 15, 11174–11186.
   Web of Science ®Google Scholar
• Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M. J.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M., Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc. Natl. Acad. Sci. 2009, 106, 1542–1547.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan, R. In The SUTENT® Story. In Process Chemistry in the Pharmaceutical Industry; K. Gadamasetti, T. Braish (Eds.); Taylor & Francis: Boca Raton, Florida, 2008; vol. 2, pp. 49–64.
   Google Scholar
• Capdeville, R.; Buchdunger; Zimmermann, J.; Matter, A. Gleevec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1, 493–502.
   PubMed Web of Science ®Google Scholar
• Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971–979.
   PubMed Web of Science ®Google Scholar
• Melnikova, I. Golden targeting protein kinases. J. Nat. Rev. Drug Discov. 2008, 3, 993–994.
   Web of Science ®Google Scholar
• Hochhaus, A.; Hughes, T. Clinical resistance to imatinib: Mechanisms and implications. Hematol. Oncol. Clin. North America, 2004, 18, 641–656.
   PubMed Web of Science ®Google Scholar
• Liu, Y.-F.; Wang, C.-L.; Bai, Y.-J.; Han, N.; Jiao, J.-P.; Qi, X.-L. A facile total synthesis of imatinib base and its analogues. Org. Proc. Res. Dev. 2008, 12, 490–495.
   Web of Science ®Google Scholar
• Huang, W.-S.; Shakespeare, W. C. An efficient synthesis of nilotinib (AMN107). Synthesis 2007, (14), 2121–2124.
   Web of Science ®Google Scholar
• Pandite, A. N.; Whitehead, B. F.; Ho, P. T. C.; Suttle, A. B. Cancer Treatment Method, WO Patent 2007/064753, 2007.
   Google Scholar
• Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; III Hunter, R. N.; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 2008, 51, 4632–4640.
   PubMed Web of Science ®Google Scholar